TREM1 is involved in the mechanism between asthma and lung cancer by regulating the Toll‑like receptor signaling pathway.
TREM1
Toll-like receptor signaling pathway
asthma
immunoassay
lung cancer
mutation analysis
Journal
Oncology letters
ISSN: 1792-1082
Titre abrégé: Oncol Lett
Pays: Greece
ID NLM: 101531236
Informations de publication
Date de publication:
Jan 2024
Jan 2024
Historique:
received:
08
09
2022
accepted:
09
06
2023
medline:
29
11
2023
pubmed:
29
11
2023
entrez:
29
11
2023
Statut:
epublish
Résumé
Lung cancer and asthma are both global health problems with significant economic consequences. Recent studies have demonstrated that asthma may be a risk factor for lung cancer. The present study aimed to explore the pathogenesis between these two diseases through a comprehensive analysis. Differentially expressed genes (DEGs) screened in the asthma-related GSE165934 dataset were analyzed to find relevant inflammatory pathways. Overlapping genes regulated by inflammatory pathways and lung cancer-DEGs from The Cancer Genome Atlas (TCGA) were obtained and subjected to survival and gene-wide mutation analyses, and nomogram construction to determine the hub gene. The hub gene was further analyzed through expression validation, immunoassays and functional experiments to investigate its role and mechanism in lung cancer. Functional enrichment analysis showed that 1,275 DEGs from GSE165934 were closely associated with the Toll-like receptor signaling pathway, and 8 overlapping genes were identified from 12 genes regulated by the Toll-like receptor signaling pathway and 3,134 TCGA-DEGs. After a series of bioinformatics analyses, it was found that triggering receptor expressed on myeloid cells 1 (TREM1) was the hub gene involved in the mechanism of asthma and lung cancer. TREM1 was also found to be a suppressor gene in lung cancer correlated with immune cells, immune checkpoint-related genes and tumor mutational burden score. Additionally, the results of Cell Counting Kit-8 and Transwell experiments demonstrated that overexpression of TREM1 could significantly inhibit the invasion, proliferation and migration of lung cancer cells. Reverse transcription-quantitative PCR and western blotting demonstrated that the overexpression of TREM1 could also significantly reduce the level of Toll-like receptor signaling pathway proteins. The present findings suggest that TREM1 is associated with the mechanism of asthma and lung cancer through its regulation of the Toll-like receptor signaling pathway. Furthermore, TREM1 may serve as a potential treatment target and prognostic indicator for patients with lung cancer.
Identifiants
pubmed: 38028174
doi: 10.3892/ol.2023.14149
pii: OL-27-1-14149
pmc: PMC10664071
doi:
Types de publication
Journal Article
Langues
eng
Pagination
16Informations de copyright
Copyright: © Yan et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests
Références
Dig Dis Sci. 2018 Sep;63(9):2251-2258
pubmed: 29736837
Carcinogenesis. 2012 Mar;33(3):587-97
pubmed: 22198214
DNA Cell Biol. 2020 Jul;39(7):1313-1321
pubmed: 32543891
Transl Lung Cancer Res. 2016 Aug;5(4):401-12
pubmed: 27652204
Curr Opin Allergy Clin Immunol. 2005 Jun;5(3):249-53
pubmed: 15864084
Cell. 2016 Mar 10;164(6):1233-1247
pubmed: 26967289
Int Forum Allergy Rhinol. 2015 Sep;5 Suppl 1:S11-6
pubmed: 26335830
Oncotarget. 2017 Feb 14;8(7):11614-11620
pubmed: 28086224
J Allergy Clin Immunol. 1998 Oct;102(4 Pt 1):531-8
pubmed: 9802359
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
J Allergy Clin Immunol. 2004 May;113(5):853-9
pubmed: 15131566
Pharmacol Res. 2020 Oct;160:105189
pubmed: 32911071
Cancer Causes Control. 2003 May;14(4):327-34
pubmed: 12846363
Oncologist. 2020 Jan;25(1):e147-e159
pubmed: 31578273
BMC Cancer. 2022 Jan 18;22(1):77
pubmed: 35042454
Front Oncol. 2022 Dec 15;12:1096449
pubmed: 36591493
Am J Respir Crit Care Med. 2014 Sep 1;190(5):549-59
pubmed: 25054566
Nat Immunol. 2019 Aug;20(8):1023-1034
pubmed: 31263278
P T. 2017 Sep;42(9):564-568
pubmed: 28890642
Virulence. 2021 Dec;12(1):570-583
pubmed: 33525982
Cancer Cell Int. 2020 Aug 26;20:406
pubmed: 32863765
Adv Dermatol. 2008;24:71-87
pubmed: 19256306
Cancer Metastasis Rev. 2011 Mar;30(1):5-12
pubmed: 21249426
Am J Respir Crit Care Med. 2013 Apr 15;187(8):798-803
pubmed: 23370915
Cancer Discov. 2015 Sep;5(9):915-9
pubmed: 26272491
Semin Cancer Biol. 2021 Nov;76:3-16
pubmed: 34242741
J Allergy Clin Immunol. 2006 May;117(5):979-87; quiz 988
pubmed: 16675322
Cells. 2020 Dec 07;9(12):
pubmed: 33297569
Expert Opin Ther Pat. 2014 Dec;24(12):1383-95
pubmed: 25363248
Methods Mol Biol. 2020;2120:249-262
pubmed: 32124325
Mol Aspects Med. 2018 Oct;63:59-69
pubmed: 30098327
J Immunol Res. 2022 Jun 2;2022:9412119
pubmed: 35692496
BMC Genomics. 2013;14 Suppl 3:S7
pubmed: 23819521
Front Immunol. 2023 May 02;14:1168920
pubmed: 37205104
Ann Oncol. 2019 Jan 1;30(1):44-56
pubmed: 30395155
Histopathology. 2004 Apr;44(4):339-44
pubmed: 15049899
Front Immunol. 2021 Feb 17;12:646523
pubmed: 33679809
J Allergy Clin Immunol. 2013 Feb;131(2):602-5
pubmed: 23273951
Eur Respir J. 2001 Feb;17(2):214-9
pubmed: 11334122
Sci Rep. 2021 Feb 25;11(1):4539
pubmed: 33633205
Methods Mol Biol. 2011;696:291-303
pubmed: 21063955
Int J Mol Sci. 2018 Oct 30;19(11):
pubmed: 30380761
Science. 1998 Dec 11;282(5396):2085-8
pubmed: 9851930
Immunotherapy. 2019 Aug;11(12):1043-1055
pubmed: 31268375
Bioinformatics. 2008 Dec 1;24(23):2798-800
pubmed: 18842599